| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/05/2011 | CA2779601A1 Vaccine compositions and methods of use |
| 05/05/2011 | CA2779578A1 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
| 05/05/2011 | CA2779459A1 Peptide compositions and methods for inhibiting herpesvirus infection |
| 05/05/2011 | CA2779257A1 Il-17a antagonists |
| 05/05/2011 | CA2778895A1 Compositions and methods for treating inflammatory disorders |
| 05/05/2011 | CA2778893A1 Dna vaccine against the yellow fever virus |
| 05/05/2011 | CA2778568A1 Antibody having activity of inhibiting hepatitis c virus (hcv) infection and use thereof |
| 05/05/2011 | CA2778540A1 Pharmaceutical composition for the treatment and prevention of a rhinovirus infection |
| 05/05/2011 | CA2778142A1 Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms |
| 05/05/2011 | CA2777705A1 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
| 05/05/2011 | CA2777698A1 Ax1 and ax189 pcsk9 antagonists and variants |
| 05/05/2011 | CA2777670A1 Process for producing influenza vaccine |
| 05/05/2011 | CA2777542A1 Ax213 and ax132 pcsk9 antagonists and variants |
| 05/05/2011 | CA2777312A1 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists |
| 05/05/2011 | CA2775903A1 Podxl protein in colorectal cancer |
| 05/05/2011 | CA2774919A1 Dosage regimen for administering a cd19xcd3 bispecific antibody |
| 05/04/2011 | EP2316960A1 Nucleic acids encoding TGEV and PRRSV sequences for improved expression of PRRSV sequences |
| 05/04/2011 | EP2316951A1 Binding domain-immunoglobulin fusion proteins |
| 05/04/2011 | EP2316925A1 Circovirus sequences associated with porcine wasting disease (PWD) |
| 05/04/2011 | EP2316924A2 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 05/04/2011 | EP2316923A2 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 05/04/2011 | EP2316922A1 Neutralizing human anti-IGFR antibody |
| 05/04/2011 | EP2316921A1 Neutralizing human anti-IGFR antibody |
| 05/04/2011 | EP2316859A1 Cathepsin S antibody |
| 05/04/2011 | EP2316858A1 Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT) |
| 05/04/2011 | EP2316857A1 Monoclonal antibodies that specifically bind to folate receptor alpha |
| 05/04/2011 | EP2316855A1 Antihuman Alpha-9 integrin antibody and use of the same |
| 05/04/2011 | EP2316853A2 Detection and modulation of slit and roundabout (robo) mediated angiogenesis and uses thereof |
| 05/04/2011 | EP2316852A1 Stabilized single domain antibodies |
| 05/04/2011 | EP2316851A1 Antibody inhibitors of GDF-8 and uses thereof |
| 05/04/2011 | EP2316843A1 Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 05/04/2011 | EP2316487A1 Recombinant IL-9 antibodies & uses thereof |
| 05/04/2011 | EP2316486A2 Cripto blocking antibodies and uses thereof |
| 05/04/2011 | EP2316485A1 Use of bispecific antibodies to regulate immune responses |
| 05/04/2011 | EP2316484A1 Antibody specifically binding to C-MET and use thereof |
| 05/04/2011 | EP2316483A1 Compositions and methods relating to the treatment of cancer and infectious diseases |
| 05/04/2011 | EP2316482A1 Transcutaneous immunostimulation |
| 05/04/2011 | EP2316481A1 Pharmaceutical composition for the treatment and prevention of a rhinovirus infection |
| 05/04/2011 | EP2316480A1 Chimeric tymovirus-like particles |
| 05/04/2011 | EP2316479A2 Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments |
| 05/04/2011 | EP2316478A1 Targeted therapeutic vaccine against P-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers |
| 05/04/2011 | EP2316477A1 Immunogenic LHRH compositions and methods relating thereto |
| 05/04/2011 | EP2316476A2 Antigenic peptides derived from telomerase |
| 05/04/2011 | EP2316466A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 05/04/2011 | EP2315834A1 The tuberculosis rv2386c protein, compositions and uses thereof |
| 05/04/2011 | EP2315781A2 Fgf-r4 receptor-specific antagonists |
| 05/04/2011 | EP2315780A1 Compositions and methods of use for therapeutic antibodies |
| 05/04/2011 | EP2315779A2 Compositions comprising antibodies to lingo or fragments thereof |
| 05/04/2011 | EP2315778A2 Compositions monovalent for cd28 binding and methods of use |
| 05/04/2011 | EP2315777A1 Therapeutic use of specific ligand in msrv associated diseases |
| 05/04/2011 | EP2315773A1 Novel compositions and methods |
| 05/04/2011 | EP2315771A2 Glycopeptide constructs and uses thereof |
| 05/04/2011 | EP2315747A2 Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
| 05/04/2011 | EP2315602A2 Methods for dosing an actriib antagonist and monitoring of treated patients |
| 05/04/2011 | EP2315601A1 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| 05/04/2011 | EP2315600A2 Compositions and methods related to sirt1 function |
| 05/04/2011 | EP2315599A1 Pharmaceutical compositions comprising antibodies binding to ebv (epstein-barr virus) protein barf1 |
| 05/04/2011 | EP2315598A1 Compositions of activated botulinum toxin type b |
| 05/04/2011 | EP2315597A1 Novel compositions and methods |
| 05/04/2011 | EP1831257B9 Humanized antibody specific for tumor necrosis factor-alpha |
| 05/04/2011 | EP1802746B1 Virosome particles comprising antigens from influenza virus and hepatitis b virus |
| 05/04/2011 | EP1778871B1 Assays and methods using biomarkers |
| 05/04/2011 | EP1663303B1 Immunogenic compositions for streptococcus agalactiae |
| 05/04/2011 | EP1581560B1 Anti-idiotypic antibodies against factor viii inhibitor and uses thereof |
| 05/04/2011 | EP1404363B1 Adjuvant composition for mucosal and injection delivered vaccines |
| 05/04/2011 | EP1383532B1 Combination therapy |
| 05/04/2011 | EP0815233B1 Novel avian cytokines and genetic sequences encoding same |
| 05/04/2011 | CN1863553B Process for preparing polysaccharide-protein conjugate vaccines |
| 05/04/2011 | CN1829529B Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
| 05/04/2011 | CN1703243B Pharmaceutical compositions directed to erb-b1 receptors |
| 05/04/2011 | CN102046803A Monoclonal antibodies to basic fibroblast growth factor |
| 05/04/2011 | CN102046660A Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| 05/04/2011 | CN102046657A Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof |
| 05/04/2011 | CN102046656A Neutralizing molecules to viral antigens |
| 05/04/2011 | CN102046651A Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof |
| 05/04/2011 | CN102046650A Infection inhibitor |
| 05/04/2011 | CN102046649A Improved analytical method for the detection of latent hepatitis c, use thereof and corresponding diagnosis kit |
| 05/04/2011 | CN102046200A Therapeutic for hepatic cancer |
| 05/04/2011 | CN102046199A Methods of treatment using anti-mif antibodies |
| 05/04/2011 | CN102046198A Flagellin polypeptide vaccines |
| 05/04/2011 | CN102046197A Coccidiosis vaccines |
| 05/04/2011 | CN102046196A Biomarker for selecting patients and related methods |
| 05/04/2011 | CN102046195A HER2/neu-specific antibodies and methods of using same |
| 05/04/2011 | CN102041266A Construction of carriers for prokaryotic expression and eukaryotic expression of candidate gene of porcine rota virus vaccines |
| 05/04/2011 | CN102041260A Grouper interleukin EcIL-1beta gene, coded protein, and preparation method and application thereof |
| 05/04/2011 | CN102041246A Human embryo retina transformed cell line for producing biological products |
| 05/04/2011 | CN102040662A Antibodies against human IL-21 receptor and uses therefor |
| 05/04/2011 | CN102040658A Schistosoma japonica polypeptide with immunogenicity and application thereof |
| 05/04/2011 | CN102038960A Method for preparing outer membrane protein H and A genes of fowl cholera and fused DNA vaccine |
| 05/04/2011 | CN102038951A Nucleic acid vaccine adjuvant designed based on MCP-1 and construction method thereof |
| 05/04/2011 | CN102038950A Novel immune adjuvant and vaccine containing same |
| 05/04/2011 | CN102038949A Method for producing newcastle disease, infectious bronchitis, egg drop syndrome and avian influenza (H9 subtype) combined inactivated vaccine |
| 05/04/2011 | CN102038948A Vaccine for controlling persistent infection of hepatitis B virus |
| 05/04/2011 | CN102038947A Method for industrially producing animal rabies vaccine by utilizing bioreactor |
| 05/04/2011 | CN102038946A Method for industrially producing pseudorabies vaccine by using bioreactor |
| 05/04/2011 | CN102038945A Method for industrially producing swine parvovirus vaccine by utilizing bioreactor |
| 05/04/2011 | CN102038944A Method for industrially producing swine fever live vaccine by using bioreactor |
| 05/04/2011 | CN102038943A Method for industrially producing porcine Japanese encephalitis (JE) vaccines by utilizing bioreactor |
| 05/04/2011 | CN102038942A Method for industrially producing porcine reproductive and respiratory syndrome (PRRS) vaccines by utilizing bioreactor |
| 05/04/2011 | CN102038941A Application of protective antigen Omp25c to preparation of brucellosis vaccine |